Biovaxys Technology Corp (BVAXF)

$0.16 +0.01 (4.03%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 33,000
Avg Vol 78,798
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 89%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell...

Industry: Biotechnology
Sector: Healthcare
Phone: 740-358-0555
Address:
146 Thirtieth Street, Suite 100, Etobicoke, Canada
Johndoe1979
Johndoe1979 Jul. 2 at 3:34 PM
$BVAXF https://x.com/i/status/2072702634805366908
0 · Reply
NewMexicats
NewMexicats Jul. 1 at 8:51 PM
$BVAXF $BIOV.CSE Decent volume today: 118k. Someone is buying in chunky lots the last day or two.
0 · Reply
NewMexicats
NewMexicats Jul. 1 at 5:02 PM
$BVAXF $BIOV.CSE https://x.com/biovaxys/status/2072357340599214326?s=20
0 · Reply
FLArnot
FLArnot Jul. 1 at 4:56 PM
$BVAXF @Ventureville I call BS, Biovaxys has been anything BUT transparent on their financials, in fact, they have straight out mis-informed the stock holders, starting back with the MCTO prior to the CTO, they claimed April 28th it would be done, then without reason, said it would be May 30th. AND STOPPED ALL BI-WEEKLY UPDATES. and May 30th has come and gone and the CTO is in full effect!!!! DO NOT GAS LIGHT! THEY HAVE BEEN EXTREMELY UNPROFESSIONAL AND IN 6 YEARS THEY HAVE ZERO REVENUE, MULTIPLE CTOs FOR FAILURE TO FILE. They may have DPX, but they don't have financial savvy.
0 · Reply
Ventureville
Ventureville Jul. 1 at 4:22 PM
$BVAXF The biotech cycle is starting to look different this year. Capital is flowing beyond large caps, and companies like $BIOV.CSE $BVAXF could benefit if risk appetite continues to improve across the sector.
0 · Reply
Ventureville
Ventureville Jul. 1 at 4:21 PM
$BVAXF Precision medicine is no longer a niche. Small-cap biotech names like $BIOV.CSE and $BVAXF are gaining attention as investors rotate back into high-upside healthcare alongside $SAVA $ALT $RXRX.
0 · Reply
Ventureville
Ventureville Jul. 1 at 4:20 PM
$BVAXF Filing delays from the accounting switch are a known hiccup, but BioVaxys has been transparent about it.
1 · Reply
JanetBSmellin
JanetBSmellin Jul. 1 at 1:54 PM
$BVAXF Ummmmm
0 · Reply
Davidendz
Davidendz Jun. 30 at 5:00 PM
$BVAXF The filing delay from the accounting switch is what they disclosed, but yeah, the lack of recent updates since mid-April is worth watching. Still, those ovarian and bladder trial readouts from January keep the platform story moving.
0 · Reply
FLArnot
FLArnot Jun. 29 at 8:17 PM
$BVAXF
0 · Reply
Latest News on BVAXF
No data available.
Johndoe1979
Johndoe1979 Jul. 2 at 3:34 PM
$BVAXF https://x.com/i/status/2072702634805366908
0 · Reply
NewMexicats
NewMexicats Jul. 1 at 8:51 PM
$BVAXF $BIOV.CSE Decent volume today: 118k. Someone is buying in chunky lots the last day or two.
0 · Reply
NewMexicats
NewMexicats Jul. 1 at 5:02 PM
$BVAXF $BIOV.CSE https://x.com/biovaxys/status/2072357340599214326?s=20
0 · Reply
FLArnot
FLArnot Jul. 1 at 4:56 PM
$BVAXF @Ventureville I call BS, Biovaxys has been anything BUT transparent on their financials, in fact, they have straight out mis-informed the stock holders, starting back with the MCTO prior to the CTO, they claimed April 28th it would be done, then without reason, said it would be May 30th. AND STOPPED ALL BI-WEEKLY UPDATES. and May 30th has come and gone and the CTO is in full effect!!!! DO NOT GAS LIGHT! THEY HAVE BEEN EXTREMELY UNPROFESSIONAL AND IN 6 YEARS THEY HAVE ZERO REVENUE, MULTIPLE CTOs FOR FAILURE TO FILE. They may have DPX, but they don't have financial savvy.
0 · Reply
Ventureville
Ventureville Jul. 1 at 4:22 PM
$BVAXF The biotech cycle is starting to look different this year. Capital is flowing beyond large caps, and companies like $BIOV.CSE $BVAXF could benefit if risk appetite continues to improve across the sector.
0 · Reply
Ventureville
Ventureville Jul. 1 at 4:21 PM
$BVAXF Precision medicine is no longer a niche. Small-cap biotech names like $BIOV.CSE and $BVAXF are gaining attention as investors rotate back into high-upside healthcare alongside $SAVA $ALT $RXRX.
0 · Reply
Ventureville
Ventureville Jul. 1 at 4:20 PM
$BVAXF Filing delays from the accounting switch are a known hiccup, but BioVaxys has been transparent about it.
1 · Reply
JanetBSmellin
JanetBSmellin Jul. 1 at 1:54 PM
$BVAXF Ummmmm
0 · Reply
Davidendz
Davidendz Jun. 30 at 5:00 PM
$BVAXF The filing delay from the accounting switch is what they disclosed, but yeah, the lack of recent updates since mid-April is worth watching. Still, those ovarian and bladder trial readouts from January keep the platform story moving.
0 · Reply
FLArnot
FLArnot Jun. 29 at 8:17 PM
$BVAXF
0 · Reply
wheresdannynow
wheresdannynow Jun. 29 at 5:59 PM
$BVAXF Government validation via programs like CBRN would be huge for DPX platform credibility. In the meantime, the positive 2026 clinical readouts in ovarian/bladder cancer keep the science moving forward. Hang in there! platforms like this take time but have big upside.
0 · Reply
wheresdannynow
wheresdannynow Jun. 29 at 5:57 PM
Precision medicine, obesity, gene editing and immunotherapy continue to dominate healthcare headlines. $BVAXF $VKTX $CRSP $BEAM $SMMT.
0 · Reply
NewMexicats
NewMexicats Jun. 26 at 7:57 PM
$BVAXF $BIOV.CSE On X/Twitter regarding the US Govt Tweet: Question: May we ask if this was a BioVaxys specific request from the capability program or a BAA request BioVaxys is responding to? BIOVAXYS Response: CPE CBRND is a separate but parallel organization to DTRA and BARDA that is under the 'umbrella' of the US Army, and they have their own discretionary budget. This meeting is not in response to any BAA; its based on a request from CPE CBRND. Hope this helps!
1 · Reply
Johndoe1979
Johndoe1979 Jun. 26 at 3:28 PM
$BVAXF https://x.com/i/status/2070529054579572955
1 · Reply
arioch1
arioch1 Jun. 25 at 8:35 PM
$BVAXF similar to my post on ceo, I'm getting used to the annual cto holiday. This years may just be a bonus length of time. Trade halts do have the benefit of denying the fake market the opportunity for manipulation thus keeping the price stable. 😜 Of course, that's a joke in itself just like passin is as ceo. Who'd even take a 2nd look here? Remember passin when the next annual vote comes around....
1 · Reply
JanetBSmellin
JanetBSmellin Jun. 25 at 8:25 PM
$BVAXF Put an order down at .06. Fidelity shows someone bought there yesterday. I know every broker is different. 🤪
0 · Reply
arioch1
arioch1 Jun. 24 at 4:39 PM
$BVAXF collaboration with the auditors would be nice
0 · Reply
NewMexicats
NewMexicats Jun. 24 at 4:38 PM
$BVAXF $BIOV.CSE https://x.com/biovaxys/status/2069819444390510812?s=20
0 · Reply
NewMexicats
NewMexicats Jun. 24 at 3:45 PM
$BVAXF $BIOV.CSE Interesting note...The DPX Anthrax study appeared in Nature Vaccines in 2019. https://www.nature.com/articles/s41541-019-0102-z
0 · Reply
NewMexicats
NewMexicats Jun. 24 at 3:45 PM
$BVAXF Fidelity appears to be incorrect. This is an active eTrade account.
2 · Reply
JanetBSmellin
JanetBSmellin Jun. 24 at 3:36 PM
$BVAXF Fidelity says last trade was .035? 🥵🥵🥵
0 · Reply
Johndoe1979
Johndoe1979 Jun. 23 at 3:36 PM
$BVAXF https://x.com/i/status/2069442252221423908
0 · Reply